W. Ted Brown, MD, PhD
Institute For Basic Research, NY
1997-1998 FRAXA Research Grant
$62,000 over 2 Years
The goal of this grant was to develop an improved test to show learning deficits in the FMR1 knock-out mouse model of Fragile X, and then to test the effects of experimental drugs (Ampakines) that may be effective in treating these deficits.
Ampakines are a class of drugs that enhance the activity of AMPA receptors in the brain, which are involved in synaptic plasticity and learning and memory. Later studies, including the following pilot clinical trial of CX516 which was funded by FRAXA, suggested that ampakines could improve cognitive function and behavior in individuals with Fragile X Syndrome.
Berry-Kravis, E., Krause, S. E., Block, S. S., Guter, S., Wuu, J., Leurgans, S., … & Brown, W. T. (2006). Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. Journal of Child Neurology, 21(10), 849-855. doi: 10.1177/08830738060210101301